Issue: June 2013
April 23, 2013
1 min read
Save

Short stature genes identified in children

Issue: June 2013
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

According to data from a large European cohort, genes involved in transcriptional regulation — NFKB1 and ZBTB38 — and growth factor signaling were associated with short stature among children with insulin-like growth factor I deficiencies.

Researchers conducted a prospective, cross-sectional, epidemiogenetic case-control study in nine European countries from 2008 to 2010 to characterize IGF-I axis status and identify a broader range of genetic associations in pediatric patients (n=275; aged at least 2 years) with short stature and normal GH (≥1 peak GH ≥7 mcg/L).

The researchers measured serum IGF-I, IGF-binding protein-III (IGFBP-III) and acid-labile subunit (ALS) levels and conducted candidate gene exome sequencing in the cohort and ethnicity-matched controls.

According to data, serum IGF-I, IGFBP-III and ALS levels were significantly correlated. However, the researchers reported differences between the prevalence of IGF-I (53%), IGFBP-III (30%) and ALS (0.8%) deficiencies.

Further data indicate that an insertion-deletion (Indel) on the IGF-I gene (P=1.2×10–5), an Indel on NFKB1 (P=1.36×10–10) and two single-nucleotide polymorphisms on ZBTB38 (P<2.3×10–6) were linked to short stature. Additionally, two single-nucleotide polymorphisms on genes related to protein kinase regulation, MAPK and Fanconi pathways also were linked to short stature (P<10–4), researchers wrote.

These data suggest other pathways that are not directly correlated with the GH–IGF-I axis have an effect on short stature in this patient population, requiring subsequent genetic investigation, they wrote.

Disclosure: Clayton reports consultancy with Ipsen. All other researchers report employment with Ipsen or Celera.